Soluble RANKL induces high bone turnover and decreases bone volume, density, and strength in mice.
Receptor activator for nuclear factor-kappa B ligand (RANKL) is an essential mediator of osteoclastogenesis. We hypothesized that administration of soluble RANKL to mice would result in high turnover and deleterious effects on both cortical and trabecular bone. For 10 days, 10-week-old C57BL/6J female mice (n = 12/group) were given twice-daily subcutaneous injections of human recombinant RANKL (0.4 or 2 mg/kg/day) or inert vehicle (VEH). Bone turnover was greatly accelerated by RANKL, as evidenced by the 49-84% greater levels of serum TRAP-5b (bone resorption marker) and 300-400% greater levels of serum alkaline phosphatase (bone formation marker). RANKL resulted in significantly greater endocortical bone erosion surface (79-83%) and periosteal bone formation rate (64-87%) vs. VEH. Microcomputed tomographic (microCT) analysis of the proximal tibia indicated a reduction in trabecular volume fraction (-84%) for both doses of RANKL. Cortical bone geometry and strength were also negatively influenced by RANKL. MicroCT analysis of the femoral diaphysis indicated significantly lower cortical bone volume (-10% to -13%) and greater cortical porosity (8-9%) relative to VEH. Biomechanical testing of the femur diaphysis revealed significantly lower maximum bending load (-19% to -25%) vs. VEH. Bone strength remained correlated with bone mass, independent of RANKL stimulation of bone turnover. These findings are consistent with the hypothesis that soluble RANKL could be an important etiologic factor in pathologic bone loss. RANKL also has potential utility as a model for studying the consequences of high bone turnover on bone quality and strength in animals.
Lloyd
S A J
SA
Department of Bioengineering, Clemson University, 501 Rhodes Research Center, Clemson, SC 29634, USA.
Yuan
Y Y
YY
Kostenuik
P J
PJ
Ominsky
M S
MS
Lau
A G
AG
Morony
S
S
Stolina
M
M
Asuncion
F J
FJ
Bateman
Ted A
TA
D000135:Acid Phosphatase / Q000097:blood; D000818:Animals; D015415:Biomarkers / Q000097:blood; D015519:Bone Density / Q000187:drug effects* / Q000502:physiology; D016723:Bone Remodeling / Q000187:drug effects* / Q000502:physiology; D019245:Compressive Strength / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D005260:Female; D005269:Femur / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000378:metabolism; D006801:Humans; D007279:Injections, Subcutaneous; D007527:Isoenzymes / Q000097:blood; D051379:Mice; D008810:Mice, Inbred C57BL; D053245:RANK Ligand / Q000494:pharmacology*; D011994:Recombinant Proteins; D000071681:Tartrate-Resistant Acid Phosphatase; D013977:Tibia / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000378:metabolism; D014057:Tomography, X-Ray Computed
D015415:Biomarkers; D007527:Isoenzymes; D053245:RANK Ligand; D011994:Recombinant Proteins; C505688:TNFSF11 protein, human; D000135:Acid Phosphatase; C000605511:Acp5 protein, mouse; D000071681:Tartrate-Resistant Acid Phosphatase